Jasper Therapeutics, Inc. financial data

Symbol
JSPR, JSPRW on Nasdaq
Location
2200 Bridge Pkwy Suite #102, Redwood City, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 441 % -54.9%
Debt-to-equity 34.2 % +124%
Return On Equity -172 % -166%
Return On Assets -128 % -129%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.3M shares
Common Stock, Shares, Outstanding 16.2M shares +7.38%
Entity Public Float 281M USD +154%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 15.3M shares +2.32%
Weighted Average Number of Shares Outstanding, Diluted 15.3M shares +2.32%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 71.6M USD +42.4%
General and Administrative Expense 22.5M USD +25.7%
Operating Income (Loss) -94.1M USD -38%
Nonoperating Income (Expense) 3.13M USD -45.2%
Net Income (Loss) Attributable to Parent -90.9M USD -45.6%
Earnings Per Share, Basic -6 USD/shares -18.7%
Earnings Per Share, Diluted -6 USD/shares -18.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 39.5M USD -63%
Marketable Securities, Current 3.4M USD
Other Assets, Current 867K USD +82.5%
Assets, Current 43M USD -60.5%
Property, Plant and Equipment, Net 1.33M USD -45.4%
Operating Lease, Right-of-Use Asset 1.56M USD +26.7%
Other Assets, Noncurrent 192K USD -83.5%
Assets 46.5M USD -59.2%
Accounts Payable, Current 8.03M USD +171%
Employee-related Liabilities, Current 1.13M USD -30.1%
Liabilities, Current 20.5M USD +104%
Operating Lease, Liability, Noncurrent 201K USD -84.4%
Other Liabilities, Noncurrent 2.26M USD 0%
Liabilities 23M USD +68.6%
Retained Earnings (Accumulated Deficit) -289M USD -45.9%
Stockholders' Equity Attributable to Parent 23.5M USD -76.6%
Liabilities and Equity 46.5M USD -59.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.8M USD -45.2%
Net Cash Provided by (Used in) Financing Activities 47.3M USD -53.4%
Net Cash Provided by (Used in) Investing Activities 4K USD
Common Stock, Shares Authorized 492M shares 0%
Common Stock, Shares, Issued 16.2M shares +7.38%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 39.9M USD -62.8%
Deferred Tax Assets, Gross 61.8M USD +31.7%
Operating Lease, Liability 2.16M USD -6.95%
Lessee, Operating Lease, Liability, to be Paid 2.25M USD -10.5%
Property, Plant and Equipment, Gross 5.15M USD -6.16%
Operating Lease, Liability, Current 1.95M USD +89.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 740K USD -37.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.26M USD +6.15%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 92K USD -52.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 740K USD -37.7%
Deferred Tax Assets, Operating Loss Carryforwards 31.8M USD +26.5%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.06M USD +26.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 740K USD
Operating Lease, Payments 356K USD +24.9%
Additional Paid in Capital 312M USD +4.73%
Depreciation, Depletion and Amortization 300K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 234K USD -52%
Share-based Payment Arrangement, Expense 7.6M USD +46%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%